6.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J
. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24.
PMC: 4544753.
DOI: 10.1038/gim.2015.30.
View
7.
OKane G, Connor A, Gallinger S
. Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer. Trends Mol Med. 2017; 23(12):1121-1137.
DOI: 10.1016/j.molmed.2017.10.007.
View
8.
LaDuca H, Polley E, Yussuf A, Hoang L, Gutierrez S, Hart S
. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2019; 22(2):407-415.
PMC: 7000322.
DOI: 10.1038/s41436-019-0633-8.
View
9.
Savanevich A, Ashuryk O, Cybulski C, Lubinski J, Gronwald J
. BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update. Hered Cancer Clin Pract. 2021; 19(1):13.
PMC: 7818718.
DOI: 10.1186/s13053-021-00169-y.
View
10.
Clark D, Michalski S, Tondon R, Nehoray B, Ebrahimzadeh J, Hughes S
. Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. Genet Med. 2020; 22(5):840-846.
PMC: 7200596.
DOI: 10.1038/s41436-020-0753-1.
View
11.
Myszka A, Nguyen-Dumont T, Karpinski P, Sasiadek M, Akopyan H, Hammet F
. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine. Fam Cancer. 2017; 17(3):345-349.
PMC: 5999175.
DOI: 10.1007/s10689-017-0050-6.
View
12.
Kurian A, Ward K, Howlader N, Deapen D, Hamilton A, Mariotto A
. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. J Clin Oncol. 2019; 37(15):1305-1315.
PMC: 6524988.
DOI: 10.1200/JCO.18.01854.
View
13.
Ramos C, Oliveira R, Rosa M, Pereira A, de Abreu R, van Helvoort Lengert A
. Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors. Curr Cancer Drug Targets. 2023; 23(11):900-909.
DOI: 10.2174/1568009623666230418101511.
View
14.
Hauke J, Horvath J, Gross E, Gehrig A, Honisch E, Hackmann K
. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med. 2018; 7(4):1349-1358.
PMC: 5911592.
DOI: 10.1002/cam4.1376.
View
15.
Parker A, Eshleman J
. Human MutY: gene structure, protein functions and interactions, and role in carcinogenesis. Cell Mol Life Sci. 2003; 60(10):2064-83.
PMC: 11138500.
DOI: 10.1007/s00018-003-3053-4.
View
16.
Kurian A, Ford J
. Multigene Panel Testing in Oncology Practice: How Should We Respond?. JAMA Oncol. 2015; 1(3):277-8.
DOI: 10.1001/jamaoncol.2015.28.
View
17.
Southey M, Goldgar D, Winqvist R, Pylkas K, Couch F, Tischkowitz M
. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016; 53(12):800-811.
PMC: 5200636.
DOI: 10.1136/jmedgenet-2016-103839.
View
18.
Bergstrom C, Pence C, Berg J, Partain N, Sadeghi N, Mauer C
. Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations. Ann Surg Oncol. 2020; 28(6):3383-3393.
DOI: 10.1245/s10434-020-09158-2.
View
19.
Gervas P, Molokov A, Zarubin A, Topolnitskiy E, Shefer N, Pisareva L
. Germline variants associated with breast cancer in Khakass women of North Asia. Mol Biol Rep. 2022; 50(3):2335-2341.
DOI: 10.1007/s11033-022-08215-1.
View
20.
Shah S, Kim Y, Ostrovnaya I, Murali R, Schrader K, Lach F
. Assessment of SLX4 Mutations in Hereditary Breast Cancers. PLoS One. 2013; 8(6):e66961.
PMC: 3694110.
DOI: 10.1371/journal.pone.0066961.
View